Blood cancer mutations may help trigger Alzheimer's, study suggests

Mutations long associated with blood cancers may also help trigger Alzheimer's disease by creating overly inflammatory immune cells in the brain, according to an international study published in the journal Cell. The unexpected finding suggests that, at least in some cases, Alzheimer's may share underlying biology with conditions such as leukaemia and lymphoma, and it points towards new approaches for both screening and treatment.

The research, led by teams in the United States including Boston Children's Hospital working with Harvard and other institutions, examined how mutations that accumulate in blood immune cells with age can end up in the brain. The work is early and based largely on laboratory and tissue analysis rather than treatments in patients, but it opens a striking new line of inquiry into one of the most challenging diseases in medicine.

This article is general information about a scientific study and is not medical advice. The findings do not change current diagnosis or treatment for dementia.

What the researchers found

The team found that the same cancer-associated mutations seen in blood immune cells can appear in microglia, the brain's resident immune cells. Their proposed mechanism is that ageing or injury weakens the blood-brain barrier, the protective boundary that normally keeps circulating cells out of brain tissue. This can allow mutated immune cells from the bloodstream to enter the brain and take on the role of microglia.

Once there, these mutated cells appear to create a more inflammatory environment, damaging nearby neurons and potentially accelerating the progression of Alzheimer's. Chronic inflammation has been increasingly implicated in dementia, and this study offers a specific genetic route by which it might be driven.

“We find that to some extent, Alzheimer's disease is a little like cancer, driven by the same mutations that drive blood cancers like lymphoma and leukaemia.”

— Christopher Walsh, study author

Why it could matter

The implications fall into two main areas. First, if specific mutations raise the risk of Alzheimer's, a blood-based genetic test might one day help identify people at elevated risk before symptoms appear, complementing the wave of blood tests already being trialled for dementia. Second, because the mutations involved are the target of existing cancer drugs, there is the tantalising possibility of repurposing medicines from oncology to tackle the brain inflammation involved.

• The study was published in the journal Cell
• Cancer-linked mutations in blood immune cells can also appear in the brain's microglia
• A weakened blood-brain barrier may let mutated cells enter the brain
• These cells appear to drive inflammation that damages neurons
• Findings hint at blood-based screening and at repurposing cancer drugs

Researchers are careful to stress that this is a long way from a treatment. Translating a mechanistic discovery into a therapy that helps patients is a lengthy process, and many promising leads in dementia research have not panned out. Still, a new and testable hypothesis about how Alzheimer's develops is valuable in a field that has struggled for decades.

How it fits the wider research picture

The finding lands amid intense activity in dementia science, including UK-led efforts to develop simple blood tests that could make diagnosis faster and more accessible. The idea that inflammation and immune dysfunction play a central role in Alzheimer's has gained ground in recent years, and linking that inflammation to identifiable genetic changes gives researchers something concrete to pursue.

“Connecting Alzheimer's to mutations we already understand in blood cancers gives us new tools to investigate and, potentially, drugs we already know how to make.”

— a researcher in neurodegeneration

Background

Alzheimer's disease is the most common cause of dementia, affecting hundreds of thousands of people in the UK and millions worldwide. Despite enormous research investment, effective treatments have been slow to emerge, and much about how the disease begins remains unclear. The accumulation of mutations in blood cells with age is a well-recognised phenomenon, but its connection to brain disease is a newer and rapidly developing area of study.

What it means

For patients and families today, the study changes nothing about how dementia is diagnosed or treated. Its value lies in the future: a fresh mechanism to investigate, a possible avenue for earlier risk detection, and a potential bridge between cancer medicine and brain health. Researchers will now need to test the hypothesis further and determine whether interventions based on it can safely slow or prevent disease, work that will take years rather than months.